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1ME aim of this study was to evaluate circulating Circulating intercellular adhesion
intercellular adhesion molecule-1 (cICAM-1) in
serum and in bronchoalveolar lavage (BAL), as a molecules in blood and
marker for the inflammatory process in patients bronchoalveolar lavage in Behcet’s with active Beh:et’s disease (BD). Circulating
ICAM-1 was tested by an enzyme linked irntnuno- disease
sorbent assay in serum and in BAL of patients
with BD. These values were compared to those of
patients with tuberculosis and to healthy
controls. Increased levels of circulating ICAM-1 &. Hamzaoui, K. Hamzaoui,2"cA A. Chabbou
3 and
were found in serum from patients with active K. &yed
4
BD compared to healthy controls (i0<0.01).
Similar levels of serum cICAM-1 were found in BD
and tuberculosis. Additionally, both BD and 1Department of Respiratory Diseases, 2Department
tuberculosis patients exhibited high levels of of Histology, 3Department of Respiratory Diseases
cICAM-1 in BAL fluid, suggesting that this and 4Department of Immunology, Facult de increase may be a result of the immune system Mdecine de Tunis, 9 rue Z. Essafi, 1007 Tunis, activation in inflammatory sites. Circulating
ICAM-1 seemed to have a good discriminative Tunisia
power in identifying active BD, being elevated in
all active stages (p < 0.01) compared to remission
BD stage. No differences were found in active BD CACorresponding Author
patients depending upon the clinical manifesta-
tions. These results suggest that cICAM-1 may be
involved in leucocyte adhesion and migration
into the vessel wall of the lung. Circulating forms
are derived from molecules expressed on the
surface of activated cells, as a result of an inflam-
matory process.
Key words: Adhesion molecules, Behqet’s disease,
Bronchoalveolar lavage.
Introduction leukin-8 (IL-8) and interferon-gamma (IFN-/),
act as leukocyte chemotactic factors, enhance
Behget’s disease (BD) is now recognized as a adhesion molecule expression and mediate
systemic disease with the vascular complications endothelial cell damage, through increased pro-
of aneurysm formation and venous thrombo- duction of oxygen free radicals.7’ Our previous
sis.’2 The underlying pathological process is a studies showed that integrins were increased in
multifocal vasculitis involving veins, capillaries sera, in cerebrospinal fluid and in broncho-
and arteries.3’4 Involvement of the pulmonary alveolar lavage cells from BD patients.9’1 Among
vascular tree in BD has been extensively studied several adhesion molecules that mediate
by Erkan and Cavdar
4 who evaluated its fre- adhesive interactions, intercellular adhesion
quency at 5-10%. The pathological process molecule-1 (ICAM-1), and its ligand are known
affecting arteries in BD was considered a result to play a pivotal role in both the migration of
of immune complex deposition in small vessels activated lymphocytes across endothelium and
leading to complement fixation and poly- basement membranes and their adherence to
morphonuclear cell activation, resulting in target tissues where putative antigens are
degeneration and occlusion of visa vasorum, located. In addition to membrane-bound ICAM-
More complex cellular pathways are actually 1, a circulating, functionally active form of this
considered as the infiltrating cells invading molecule has been described, and is denoted
inflammatory sites are mainly CD4 + lympho- clCAM-1.
cytes, macrophages and B cells, present in the In the present study we searched for elevated
vascular adventia and media.5’6 These inflamma- levels of clCAM-,1 in sera and in bronchoalveolar
tow cells together with endothelial cells produce lavage (BAL) from patients with active BD. Two
cytokines,
6 some of which, such as interleukin-1 groups were studied, tuberculous patients and
(IL-1), turnout necrosis factor (TNF-a), inter- healthy controls.
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Materials and Methods Immunoassays: Circulating ICAM-1 levels were
measured by a commercially available ELISA
Patients: Forty patients with BD were character- system (Bender & Co., Vienna). This kit uses a
ized according to the criteria of the International horseradish peroxidase conjugated monoclonal
Study Group of Behget’s Disease. Twenty-eight anti-human clCAM-1 antibody. The company’s
were in active stage, and had recurrent oral and suggested procedures were followed without
genital ulcerations and uveitis associated with modification, and the plates were read at a wave-
one or more other clinical manifestations as length of 450nm in an ELISA reader. Circulating
shown in Table 1. These patients were not ICAM-1 concentrations were determined by corn-
treated. Eleven patients with active BD were sus- paring the mean absorption of duplicate samples
pected of having pulmonary manifestations and with that of a standard curve. Forty healthy
underwent a bronchofibroscopy with broncho- donors (aged 45 + 9 years) served as controls to
alveolar lavage. Macroscopic lung involvement establish normal values of clCAM-1.
was confirmed in seven cases (chronic cough
associated to interstitial shadows on the chest Peripheral blood samples: Peripheral venous
roentgenogram or pulmonary aneurysms). As blood was taken from all patients and from all
control subjects, ten patients (male, mean age control subjects. Serum was separated from
45 years, range 25-49 years) with no evidence clotted whole blood after centrifugation at
of interstitial lung disease were studied. They 400 x g for 10 min at room temperature and
were undergoing routine bronchoscopy for sus- stored at -70C before measuring circulating
pected bronchial carcinoma. In all of them, the adhesion molecules.
lung lavage was roentgenographically normal,
and BAL cytology showed a normal differential Bronchoalveolar lavage: The chosen lobe was
count. Another seven patients (male, mean age lavaged with 50ml aliquots of sterile 0.9%
50 years, range 37-56 years)with confirmed sodium chloride, as reported recendy.
2 The
pulmonary tuberculosis were also studied, lavage fluid was gently aspirated after each
Informed consent was obtained from all subjects aliquot and collected into a sterile, siliconized
for the study, glass botde and maintained at 4C. The lavage
Table 1. Clinical manifestations of active Behc;et’s disease
Patient Age Sex Oral Genital Ocular Skin lesions CNS
b Pulmonary
32 M + + +
2 45 M + + + +
3 25 M + + + +
4 36 M + + + +
5 27 M + + + + +
6 48 M + + + + +
7 29 M + + + + +
8 43 M + + + + +
9 33 M + + +
10 43 M + + + + +
11 39 M + + + +
12 38 F + + + +
13 42 M + + +
14 52 M + + +
15 33 M + + +
16 35 F + + + +
17 36 M + + + + + +
18 27 M + + + +
19 48 M + + +
20 37 M + + +
21 46 M + + + +
22 38 M + + +
23 25 M + + + + +
24 34 M + + + +
25 29 M + + +
26 32 M + +
27 27 M + +
28 36 M + +
aErythema nodosum, cutaneous, vasculitis, pyoderma or pustules.
bMeningoencephalocele, seizures, cranial nerve palsy, quadriparesis.
Cpulmonary interstitial shadows (aneurysm on the right main branch or on the upper lobe pulmonary artery).
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fluid was filtered through coarse gauze and cen-
trifuged at 350 x g at 4C. The supernatants
were concentrated by evaporation and recon-
stituted in I ml normal saline and studied by
ELISA for clCAM-1.
Statistical analysis: All results are expressed as
mean _+ standard deviation (S.D.). Onlyp < 0.01
degree of significance was accepted. The Mann-
Whitney U-test was used to compare the levels of
circulating adhesion molecules between the dif-
ferent groups.
Table 2. Circulating ICAM-1 in serum from patients with BD
Diagnosis No. clCAM- (ng/ml)
BD patients 40 582 -I- 47*
BD in active stage 28 694 -i- 37*
BD in remission stage 12 387 -I- 69
BD with pulmonary manifestations 10
BD with CNS involvement 7
BD with skin lesions 14
BD with ocular manifestations 19
652 ___
39*
714 .1_67"
650 +_ 35*
590 -I- 93*
clCAM-1 was increased in active BD (*p< 0.01), compared to BD in
remission stage. No differences were found between patients with
pulmonary manifestations and extrapulmonary involvements. Values are
expressed as mean ___
S.D.
Results
Serum levels of clCAM-I: Circulating ICAM-1 was
detected in all normal healthy controls
(350 _+ 24ng/ml) (Fig. 1). Patients with active
tuberculosis exhibited high levels of clCAM-1
molecule (570-t-96ng/ml), when compared to
healthy controls (Fig. 1). Patients with BD
showed high levels of clCAM-1 (584 -t- 47U/ml),
when compared to healthy controls (p < 0.001)
(Fig. 1 and Table 2). No differences were
observed in serum clCAM-1 between BD patients
and tuberculous patients.
Patients with BD were studied according to
their clinical stage. Patients with active BD had
high levels of circulating clCAM-1 (694 __
37 ng/
ml), when compared to BD patients in remission
stage (387-t-69ng/ml) (Table 2). Patients with
active BD were compared for circulating adhe-
sion molecules, according to their clinical mani-
festations. No differences were found between
patients with pulmonary or with extrapulmonary
manifestations (Table 2).
BAL fluid level of cICAM-I: BAL fluid from ten
BD patients, seven tuberculous patients and
ten healthy controls was studied for circula-
ting adhesion molecules (Fig. 2). BAL fluid
from healthy controls showed limit levels of
clCAM-1 (105 -t- 28ng/ml). BD patients with
pulmonary manifestations exhibited high levels
of clCAM-1 (635 +__ 47 ng/ml). Levels in BAL fluid
from patients with tuberculosis (734 _+ 96 ng/ml)
were increased to levels similar to those in BD
patients.
Discussion
Circulating ICAM-1 levels in serum and in BAL
fluid from patients with active BD and having
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FIG. 1. Enzyme-linked immunosorbent assays for clCAM-1 mole-
cule in serum from patients with Behqet’s disease (BD; n =40),
in active (n =28) and remission stage (n 12) compared with
patients with tuberculosis (Tuber; n =7) and healthy controls
(n 10). Vertical bars represent means -1, S.D.
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FIG. 2. Enzyme-linked immunosorbent assays for clCAM-1 mole-
cule in bronchoalveolar lavage from patients with Behet’s
disease in active stage (BD; n 10), compared with patients
with tuberculous (Tuber; n=7) and healthy controls (n= 10).
Vertical bars represent means -t- sd.
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pulmonary manifestations were increased at the
same level as in tuberculous patients, compared
to healthy controls. The pathological importance
of circulating adhesion molecules has not yet
been fully delineated. The release of ICAM-1
from the surface may be a mechanism to control
cell adhesion. Circulating ICAM-1 may be a
byproduct of alteration in cell adhesion molecule
expression and cell adhesion, characteristic of
inflammation. BD in the active stage was char-
acterized by an increase of clCAM-1 compared to
BD in the remission phase. The elevated serum
concentration of 1CAM-1 in active BD suggests
that it may be a useful marker of disease activity.
Thus, circulating ICAM-1 was raised in all active
BD patients, independently of the lesion sites.
This increase was specific to the activated stage,
reflecting immune system activation.
The most important point was the increased
clCAM-1 in BAL fluid from BD patients. A similar
increase was previously reported in pulmonary
tuberculosis13 and idiopathic pulmonary fibro-
sis,
3 that are characterized by extensive inflam-
mation. In BD, lymphocytes are responsible for
the recruitment of inflammatory cells to the
lung,
14 by releasing a wide array of cytokines.
Patients with active BD are characterized by an
increase of INF-3,,
15 TNF-,8’16 IL-8,
8 and IL-68’12
production. These cytokines can up-regulate
adhesion molecule expression on some endo-
thelial cells.7 The presence of circulating adhe-
sion molecules in BAL from BD patients
provides a possible mechanism by which these
inflammatory leukocytes are attracted to the
lesion site, leading to development of the
disease. The main features of lung involvement
in BD consist of vasculitis forming multifocal
aneurysm and thrombosis of the pulmonary
artery.
8-2 Histological examination of the
aneurysm wall reveals an inflammatory exudate
containing lymphocytes and polymorphonuclear
leukocytes invading the adventia of the artery.
17
ICAM-1, the LFA-1 receptor of which is expres-
21 sed on all leukocytes, probably mediates the
adhesion of neutrophils, monocytes and lympho-
cytes to vascular endothelium. LFA-1 was found
to be increased in BAL lymphocytes from active
BD patients,9 facilitating their transendothelial
migration. Atherosclerotic aortic aneurysms and
plaques2-23 are also associated with elevated
clCAM-1. The detection of cICAM-1 may serve as
a useful diagnostic tool in diseases where leuko-
cyte endothelial cell interactions play an impor-
tant role.
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